{"name":"Accent Therapeutics","slug":"accent-therapeutics","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxQT1BxOXJ4SHFXUXczR1Bfa0hZbmVfTnYtMktxaGJXdWs0MWxweF9jUXd0LUtlMlRLUkYxcUItb0NOMTR0NFl6NUNoMjJKaFBrOGRFVHJydWNYbktFQkJCQmNXYVBERDJsbnJrRms1enZiQjNBeV9halk4ZW1VUkV4dVpkNDFfazZ4VFBPRWJ1VmpCdnJfLUtZV3V2UXdiM0d4NE5RSmFxZHFwM1l6LTNENmVpY1QzVXpNb3ZlU00xU2MzT3dKWGQ0?oc=5","date":"2026-02-11","type":"pipeline","source":"Genetic Engineering and Biotechnology News","summary":"SLAS Highlights: Opening Keynote Spotlights Novel Target in Genomically Unstable Tumors - Genetic Engineering and Biotechnology News","headline":"SLAS Highlights: Opening Keynote Spotlights Novel Target in Genomically Unstable Tumors","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-wFBVV95cUxOSVJaMHFSYlJvdksyLW1IUkx1R3l4THUxX1Y4T0k5eHI1Y2tBTElSSC1qTURBVmU5NThZVFpFTXNhbHJwbDlGbl9CanRETFVVektFMXJPMmNTOFB0WTk4d09Gak84RzB5WFRsSWQyUUU1bWRlc1BEZnZmc3VwWC1RY2VKLXpVN1g4QkswSUp5eW8tUkxJSUF1NnhCRnBrZUVzbDYwbHpnTVFBMDdyNE9CNGFvRUFJMkhlRndrcXhSTmNENWZOOVJrUlpWNFlBVkY1bFlrSm1uSVlnNDUxeUZUR0VMYTFpSDh0bWY5ejl5dWRKUEY5QVZkTE95UQ?oc=5","date":"2026-01-28","type":"trial","source":"businesswire.com","summary":"Accent Therapeutics to Utilize Inocras’ CancerVision™ and MRDVision™ Platforms in Phase 1/2 ATX-295 Clinical Study - businesswire.com","headline":"Accent Therapeutics to Utilize Inocras’ CancerVision™ and MRDVision™ Platforms in Phase 1/2 ATX-295 Clinical Study","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifEFVX3lxTE9yREdyRjB6dExob0hfQjNUeFV4MERBZVg2WTNoNU9SVnFGbk1ZbmUtXzdNLXJBMFV1WTVUbkMxX00xMDRlTnE1TE9wa1R1UklidXJESDBvbmswUm1mRzhzYlNpVFdSUGd4THFaRjFUZzktWHJxOHJsT0RSckw?oc=5","date":"2026-01-16","type":"pipeline","source":"Crunchbase","summary":"Accent Therapeutics - Tech Details - Crunchbase","headline":"Accent Therapeutics - Tech Details","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxQODZYMWx2dEU2T1dSQlNOTG5rdE9sYndjbnBjbW9iREdzbVQtQ3pWTHkxSTBNbjFER1ZHLVpudU1DUVRlTXhrZ19zVl9fb2c4NnoxVVdCazkxTkdiV2ZDa0NEUHNhY2RQZkcxYl9JX09KNUlRVHRLYU9VdHhOVlEtWUtWUzlrT0hpMmF6WFNpVDlBX0R0aHdz?oc=5","date":"2025-10-15","type":"trial","source":"Endpoints News","summary":"Boehringer makes an ADC deal with AimedBio; EyePoint’s $150M stock sale - Endpoints News","headline":"Boehringer makes an ADC deal with AimedBio; EyePoint’s $150M stock sale","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxNR1hUZWFiT2xGUlJ2WWJ1UC04V0ptZDd0cGgxandFRHBkUXl1N0k5OUlxZmJncHpQWHFQcHFSbWk5LVQzVjk0cWs5cDR2T0haT2RjVW83b2I5NzVUTl82M0pkeGtHa0VDbVAyTHRfcmxCWnNEWi1NcXo4MFBaNWlvSVRNWXlVRFJRY3AxRTcwcll3aHhtay1IOEdrSlA3TGNGWTNJ?oc=5","date":"2025-10-09","type":"pipeline","source":"BioWorld News","summary":"Boehringer Ingelheim gains Accent preclinical cancer program - BioWorld News","headline":"Boehringer Ingelheim gains Accent preclinical cancer program","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3AFBVV95cUxQYVRLX2MyVUw5WVZTU2xNMWJnVE9EU045TEIwTHNuZFhoa1RUTUNNbExqaDFPd1lDRHRiYUhfSHFkamR5cnVfX3BMOGhIOE1vZkpqTmsxa1lwUHVMcU1OUU1uZHIydmllN0NCWXBldXdkUTBEUGx5QklpeGxrNjhhUEVJYzdzVHVtWnZ3RmtrOUJURnhxQWNyREpfRDNEWUhIZ3BQWENibzFacVd4X0dINndNZWpTTVpwNEFLT0s4LTFydy1peWdvS0YycWFJcDkxOWFLYUxVNXlaUklh?oc=5","date":"2025-10-08","type":"pipeline","source":"prnewswire.com","summary":"Boehringer Ingelheim Obtains Novel Preclinical Oncology Program from Accent Therapeutics - prnewswire.com","headline":"Boehringer Ingelheim Obtains Novel Preclinical Oncology Program from Accent Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxNMHgzalZuVHliTGNNTlBoTWJQdkpKeE9BeGdySzhTRGJLVUx1al9hN0xkUUVvRHBPRHRaNXFpd0xCNVJ2aThUOXlaS3lFYmxpN1N4SEItX1NCU3VTVUFRR25wR3FVcXJ1ZzdEWVZwVmJWTFJnaThuMEpVSGhXeWZDYXN1OWdSLVBDbTFiN0pTc19KOFNqSkpOUXBwNzlWS0lWNjM2THJxTmhncnN4aklaYnlmZDhNcnh3dThESFYxNEpYajR3RUE?oc=5","date":"2025-10-08","type":"deal","source":"Contract Pharma","summary":"Boehringer Ingelheim Acquires Preclinical Oncology Asset from Accent Therapeutics - Contract Pharma","headline":"Boehringer Ingelheim Acquires Preclinical Oncology Asset from Accent Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE1OaVpRemRsTFB2Qnk3NVVUSE4wa1QybGQyTjhoNS14QzlySDNDR2tlM2tVRzF2cmZnR05zZkZZS094ZTh6U1Y5dll2UVZmUGRvN09z?oc=5","date":"2025-10-08","type":"pipeline","source":"FirstWord Pharma","summary":"Boehringer picks up preclinical cancer asset from Accent - FirstWord Pharma","headline":"Boehringer picks up preclinical cancer asset from Accent","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAJBVV95cUxPZ2xOTUh4RkwxNEZtN3AwZmZxX3BxQS1LWXNmalVabGYxQVhmZ3RJa0dESnpSV3dwajNxMDhEM0xzQjBTRTVyM2w5anYzWl9iSl95WjVlTmdNdzZocGlqS3NmNXhVY19iSE1BeFFJZ2RtN2s5aFBTcjZRQm1nVWZZZktDVTA5ZjNodUlfeHVWc1VPMlFEbW03aGkzVnl3eDYwQll1SHJOR1BQbmJmZzNpcnZfbTZMSTU5UVgtUXB1S1ZfcFBFOExseW9CaE10ZENmb3NnMDhtYVpjVUxJSUE0amphdWpDTjFYR0lheXdqVC0yQTBsdVlMWl9lb3JWY0s0aUNZQw?oc=5","date":"2025-05-22","type":"trial","source":"prnewswire.com","summary":"Accent Therapeutics Announces Trial in Progress Poster for First-in-Human Study of ATX-559 at 2025 ASCO Annual Meeting - prnewswire.com","headline":"Accent Therapeutics Announces Trial in Progress Poster for First-in-Human Study of ATX-559 at 2025 ASCO Annual Meeting","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMie0FVX3lxTE9pX0JOZkxxOHgtako3R2J1dExJUi04dEFNcUJSbi1GM3hNeExvUXJhYVJLbXFvMDQ2QlBBUDA2WjYxbW8td185ZkJhNXFKSWdyZ0FBRzRMUkNIR0hKVW5feEdlTGhoUVJidmVQaHZoVFppeGdPYWtKc3haWQ?oc=5","date":"2025-04-16","type":"trial","source":"Clinical Trials Arena","summary":"Accent Therapeutics starts dosing in trial of KIF18A inhibitor for solid tumours - Clinical Trials Arena","headline":"Accent Therapeutics starts dosing in trial of KIF18A inhibitor for solid tumours","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxNX2RSZTBBb3lFd3gxMVlRWnk5ajA3T0prRzRRcHptdWExaThqVTBTY1hBOVdIdVRjU0lpaFg3RlFud1oySnZHZWJhVnE5aF9aTmNJY1VVUG9jd2dhTkpldHpqY1NjQU1pS2Z1UVRnMzBZbmNnUm52Q3NvTlptVzNvcmI4aFNpUWZ2UW5IYkpScnlyMDc0eGV1WTRzTE4?oc=5","date":"2024-01-23","type":"pipeline","source":"Fierce Biotech","summary":"Two more pharmas practice their Accent, invest in $75M series C round - Fierce Biotech","headline":"Two more pharmas practice their Accent, invest in $75M series C round","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxNUVA2bkx6NnJtVXlUQTJLcVIwdHNOeGR0THZTeWtOaFlSYzd0Z2Y1WnhnTm5uMTA1QTFseVFhUHNWclJaWGlXQVRwYW9aY25udHlUV3U2dXg0M21DYnpJM0ppU3lIVl8xV0xfcXNpSlFBdXFYN3prX1A3X3JZeTVKeHNuZWVqdl9ZcXc?oc=5","date":"2024-01-23","type":"pipeline","source":"BioPharma Dive","summary":"Pharmas back Accent’s plan to make RNA-targeting cancer drugs - BioPharma Dive","headline":"Pharmas back Accent’s plan to make RNA-targeting cancer drugs","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}